Go to content
UR Home

TIMolol nasal spray as a treatment for epistaxis in hereditary hemorrhagic telangiectasia (HHT) – study protocol of the prospective, randomized, double-blind, controlled cross-over TIM-HHT trial

URN to cite this document:
DOI to cite this document:
Andorfer, Kornelia E.C. ; Seebauer, Caroline T. ; Koller, Michael ; Zeman, Florian ; Berneburg, Mark ; Fischer, René ; Vielsmeier, Veronika ; Bohr, Christopher ; Kühnel, Thomas S.
Date of publication of this fulltext: 17 Jul 2023 16:26


BACKGROUND: Hereditary hemorrhagic telangiectasia (HHT) is an inherited orphan disease, in which the absence of capillary beds between arterioles and venules lead to arteriovenous shunts. Epistaxis is the core symptom. Several case reports have described the nonselective beta-adrenergic receptor antagonist timolol as a successful treatment method of nosebleeds due in HHT patients. OBJECTIVE: ...


Owner only: item control page
  1. Homepage UR

University Library

Publication Server


Publishing: oa@ur.de
0941 943 -4239 or -69394

Dissertations: dissertationen@ur.de
0941 943 -3904

Research data: datahub@ur.de
0941 943 -5707

Contact persons